Some of the major segments in this market include immunochemistry testing, microbiology testing and molecular diagnostics testing. Historically, immunoassays constituted the largest segment in the IVD market which are conducted for determining presence of infectious disease in a patient. Present day technology for testing infection disease include enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassays which require more amount of protein biomarker than molecular diagnostics. However, the market for molecular diagnostics is rapidly growing with the increasing adoption of this technology in place of antigen testing by immunoassays. Molecular diagnostics possess advantages such as high specificity which help detect even minute amount of protein biomarkers. This helps in early detection of infectious diseases and becomes easier to mitigate the result. The global market for infectious disease IVD market is expected to driven by development of newer assays for diagnosis and treatment of infectious diseases. The changing demographics in the world which majorly include aging population and rising incidences of diseases of affluence are propelling the growth of infectious disease IVD market.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=210342
On the basis of geography, the global market for infectious disease is segmented into four major regions, namely, North America, Europe, Asia Pacific and Rest of the World. Although industrially developed nations in Europe and North America account for largest share in the global market, high growth is witnessed in the emerging markets of Asia-Pacific regions. The demand for infectious diseases in vitro diagnostics in Asia-Pacific is attributable to high population growth, increasing awareness and investments in healthcare infrastructure. The big players in the market are focusing in this geography to compensate their slowing business in highly competitive western markets. The competitiveness in the industry augmenting each day with more number of players seeking to leverage benefits of this growing market. The leading players in the diagnostic market are acquiring smaller technology companies to produce companion diagnostic tests; while the pharmaceutical companies enticed by the opportunities in the IVD market are either investing or collaborating with diagnostic devices companies to extend their drugs market post patent expiry. Roche Diagnostics and Abbott Laboratories are couple of major companies in the market which have added advantage of synergy between their diagnostic solutions and pharmaceutical solutions.
Some of the major companies in the global infectious disease IVD market include Roche Diagnostics, Abbott Laboratories, Becton Dickinson (BD) Company, Gen-Probe, Inc. (a part of Hologic, Inc.), Alere, Inc. (formerly Inverness Medical Innovations, Inc.), Luminex Corporation, Orhto-Clinical Diagnostics (Carlyle Group) LifeScan, Inc. (a Johnson & Johnson company), Siemens Healthcare, bioMeriux SA, and Bio-Rad Laboratories, Inc.
This research report analyzes this market depending on its market segments, major geographies, and current market trends.
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
For More Information Kindly Contact:
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States – 12207
USA-Canada Toll Free: 866-997-4948
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://researchreportlife.blogspot.in//